JUNIPER BIOLOGICS ACQUIRES TG-C LD CELL-MEDIATED GENE THERAPY FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

600 million US dollars acquisition will see Juniper Biologics deliver the world’s first cell-mediated gene therapy to approximately 300 million patients in Asia Pacific, Middle East and Africa

SINGAPORE, April 13, 2022 /PRNewswire/ — Juniper Biologics, a science-driven healthcare company focused on the research, development and commercialization of novel therapies, today announced that it has been granted licensing rights to develop and commercialize TG-C LD (TissueGene-C low dose) for the treatment of osteoarthritis of the knee.

the 600 million US dollars license agreement that covers Asia Pacific, Middle East and Africa was signed with Kolon Life Science and is Juniper Biologics’ second acquisition in as many months. Under the terms of the partnership, Juniper Biologics will be responsible for the development and commercialization of TG-C LD to healthcare professionals and hospitals in these regions. Kolon Life Science will be responsible for supporting development as well as supplying TG-C LD.

TG-C LD is an experimental non-surgical treatment that has been hailed as the world’s first cell-mediated gene therapy for osteoarthritis of the knee,[i] which is the most common form of arthritis.[ii] According to research, osteoarthritis is estimated to be the eleventh[1] leading cause of disability worldwide with approximately 300 million patients Asia Pacific and Middle East and Africa alone, suffering the debilitating effects of degenerative joint disease. It is one of the greatest unmet medical needs among musculoskeletal disorders, with the risk increasing with age.[iii].

The first cell-mediated gene therapy, TG-C LD targets knee osteoarthritis with a single intra-articular injection. Kolon TissueGene, licensee for TG-C in United States (not TG-C LD), has already completed a Phase 2 clinical trial in United States, with initial data demonstrating long-lasting pain relief and improved mobility after a single injection into the knee joint, possibly for up to 2 years. Phase 3 clinical trials in United States including 1,020 patients are currently underway to confirm the safety and efficacy of TG-C. In addition to confirming the statistically significant reduction in pain and functional improvements seen in the Phase 2 clinical trial in the United States, the trials are designed to show delay in disease progression to achieve a DMOAD (Disease Modifying Osteoarthritis Drug).

CEO of Juniper Biologics, Raman Singhsaid: “We are always looking to identify areas where we can make the most difference and TG-C LD offers substantial relief to patients with osteoarthritis of the knee who would otherwise require surgery or other treatment options. We are committed to providing innovative treatments to treat osteoarthritis of the knee through cartilage regeneration and believe that this innovative experimental treatment will bring relief to millions of patients in the region.”

“We are excited to work with Juniper Biologics to open new avenues for patients to access this innovative experimental cell therapy. It would be a validation of our technology and its market value,” said Woosok Lee, President and CEO, Kolon Life Science. “We believe that patients Asia Pacific, Middle East and Africa will stand to benefit from TG-C LD as we go through the rigor of establishing it as a global standard treatment option. »

About Juniper Biologics
Backed by The Sylvan Group, Juniper Biologics is a science-driven healthcare company focused on delivering novel therapies to improve patient health and quality of life, establishing a growing presence in oncology, rare/orphan diseases and gene therapy. It was founded on a vision to provide treatments for unmet medical needs focused on the specialist therapeutic areas where it can make the most difference. Through bold and transformative science, Juniper Biologics is committed to creating possibilities that have the potential to become the next generation of life-changing medicines for patient communities in China, Japan, Asia, Australia, New Zealand, Middle East and Africa.

About TG-C [TissueGene-C] TG-C [TissueGene-C] is a first-in-class cell-mediated gene therapy targeting knee osteoarthritis through a single intra-articular injection. Clinical trials held in United States and abroad have demonstrated pain relief and increased mobility, as well as indicators towards a decrease in the progression of osteoarthritis and improvements in joint structure. The allogeneic cell therapy product could provide an alternative to traditional treatment and surgery, or delay the progression of osteoarthritis to minimize the need for multiple surgeries. The TG-C cell therapy product is developed in two dosages: TG-C developed in United States by Kolon TissueGene and TG-C LD developed in Korea by Kolon Life Science.

About Kolon Life Science

Kolon Life Science has been developing innovative cell and gene therapies since its inception in 2000. It holds an exclusive license to develop and commercialize TG-C LD in Asia, which was granted by the original developer of TG-C, Kolon TissueGene. Kolon Life Science’s representative pipeline includes KLS-2031 which targets neuropathic pain and KLS-3021 which is an oncolytic viral therapy. In addition to its biopharmaceutical business, the Company is also engaged in the provision of active pharmaceutical ingredients (APIs), ecochemicals, including antimicrobials for personal care and industrial applications, as well as treatment solutions for water. For more information, please visit www.kolonls.co.kr/eng.

For more information, please visit: www.JuniperBiologics.com

SOURCE Organic Juniper

About Antoine L. Cassell

Check Also

India records success with BP treatment and control

India’s hypertension control initiative, launched in 2018, has expanded to over 100 districts India’s hypertension …

Leave a Reply

Your email address will not be published.